Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now early-phase tilt

Diabetic Retinopathy: early-phase trial registry

15 of 58 indexed Diabetic Retinopathy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #244 of 28,707 conditions by registered trial count.

58 US clinical trials · 15 currently recruiting · #244 of 28,707 conditions by registered trial count

Diabetic Retinopathy: 58 US clinical trials tracked, 15 recruiting.

Diabetic Retinopathy is the subject of 58 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 4 of these trials.

Enrollment posture brief

Registry condition diabetic-retinopathy

OPEN 15 | RECR 26% | LATE 8 | EARLY 21 | RANK #244 | SPON 4

Nearest open-share peer: Coronary Artery Disease (26% recruiting · 220 trials)

Recurrent Acute Myeloid Leuk51.7%Anesthesia43.1%Exercise41.4%Non-alcoholic Fatty Liver Di32.8%Diabetic Retinopathy (this)26%
Open-enrollment share among volume-matched conditions near Diabetic Retinopathy

Diabetic Retinopathy lists 15 open slots (26% of 58 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetic Retinopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetic Retinopathy is recruiting below its size-band peers.

    15 of 58 indexed trials (25.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Diabetic Retinopathy trials is spread across many organizations.

    National Eye Institute (NEI) accounts for 4 of 58 trials (6.9%). 45 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetic Retinopathy enrolment sits around 178 participants.

    Median target enrolment is 178 among the 58 trials that report a genuine target (sentinel values excluded). 20 of those (34.5%) plan for fewer than 100 participants.

  4. Diabetic Retinopathy splits between interventional and observational designs.

    39 interventional and 19 observational studies make up this index (67.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 18Phase 213Phase 37Phase 41

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 13
Phase 3 7
Phase 4 1

Named interventions

Most-linked intervention names on Diabetic Retinopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
THR-149 dose level 3 Drug
2 trials
THR-149 dose level 2 Drug
2 trials
THR-149 dose level 1 Drug
2 trials
Placebo Other
2 trials
Peribulbar Triamcinolone Acetonide Drug
1 trials
RG7774 Drug
1 trials
Deferred aflibercept Drug
1 trials

US sites by state

Facility locations filed on Diabetic Retinopathy trials. A trial with sites in several states counts in each.

California 21 trials
Florida 18 trials
Maryland 13 trials
Georgia 10 trials
Arizona 10 trials
Illinois 9 trials
Texas 7 trials
Connecticut 7 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetic Retinopathy page

58 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Retinopathy condition card totals 58 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.